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PENILAIAN FARMAKOEPIDEMIOLOGI DAN KOS BAGI 
MEMPRESKRIPSIKAN UBAT DI LUAR INDIKASI DALAM KALANGAN 
PESAKIT PEDIATRIK DI HOSPITAL SUNGAI BULOH, SELANGOR, 
MALAYSIA 
 
ABSTRAK 
Penggunaan ubat di luar indikasi sering berlaku di kalangan pesakit pediatrik. 
Data bagi penggunaan dan kos ubat-ubat yang digunakan di luar indikasi serta alasan 
di sebalik keputusan kuantitatif dari kajian sebelumnya, masih belum dikaji lagi. 
Penyelidikan ini bertujuan untuk mengkaji, menilai dan menyifatkan penggunaan ubat 
di luar indikasi di kalangan pesakit pediatrik di Hospital Sungai Buloh. Empat kajian 
telah dijalankan dengan menggunakan kaedah bercampur untuk menepati objektif-
objektif penyelidikan. Kaedah kualitatif digunakan untuk menyediakan maklumat 
dasar mengenai kesedaran, pengetahuan, sikap dan pendapat berkaitan penggunaan 
ubat di luar indikasi bagi pesakit pediatrik. Kaedah kuantitatif pula digunakan untuk 
mengenalpasti tahap, jenis dan kos ubat yang digunakan di luar indikasi serta 
mengenalpasti keperluan pembelajaran di kalangan doktor pediatrik dan pegawai 
farmasi berkaitan penggunaan ubat di luar indikasi. Kajian-kajian ini telah dijalankan 
di kalangan pegawai farmasi dan doktor di Jabatan Farmasi serta Jabatan Pediatrik, 
Hospital Sungai Buloh. Kebanyakan peserta kajian (93.4%) mengetahui terma 
pengunaan ubat di luar indikasi. Seramai 60% peserta kajian tidak sedar bahawa 
mereka mempreskrib dan mendispen ubat di luar indikasi. Terdapat perbezaan di 
antara pendapat peserta kajian berbanding keputusan kajian-kajian yang telah 
dilakukan sebelum ini. Peserta kajian lebih prihatin terhadap aspek keselamatan 
(63.7%) berbanding aspek efikasi (40.7%) ubat yang digunakan di luar indikasi. 
Penggunaan bukti saintifik disarankan sebagai langkah pengawalan yang penting. 
xvii 
 
Perbincangan bersama ibubapa pesakit serta pengambilan keizinan untuk menjalani 
rawatan, dianggap sebagai langkah yang penting semasa ubat digunakan di luar 
indikasi. Aktiviti ‘merujuk’ disarankan semasa membuat keputusan untuk 
menggunakan ubat di luar indikasi serta ciri-ciri panduan untuk praktis tersebut. Di 
antara 4101 pesanan ubat yang diberikan kepada 900 pesakit, 52.1% adalah pesanan 
untuk penggunaan ubat di luar indikasi. Kos ubat di luar indikasi adalah sebanyak 
RM61586.65 (54.1%) daripada jumlah kos ubat. Kebanyakan peserta kajian (95.6%) 
menunjukkan minat untuk mendapatkan tunjuk ajar mengenai penggunaan ubat di luar 
indikasi. Polisi atau garispanduan dinilai sebagai penting (73.6%) untuk ciri-ciri 
latihan dan panduan. Secara kesimpulannya, penggunaan ubat di luar indikasi adalah 
ketara di kalangan pesakit pediatrik di Hospital Sungai Buloh. Maklumat dasar 
berkenaan pengetahuan serta pandangan pegawai farmasi dan doktor adalah berbeza 
dengan penemuan kajian yang dijalankan sebelum ini. Penggunaan ubat di luar 
indikasi melibatkan separuh daripada jumlah kos ubat dan ini menekankan 
kepentingan kajian ‘cost-effectiveness’ dijalankan di masa hadapan.  Usaha perlu 
diambil untuk memenuhi keperluan pembelajaran yang telah dinyatakan dari segi 
mengenalpasti ubat yang digunakan di luar indikasi, integrasi bukti saintifik, 
penekanan terhadap keselamatan pesakit, pengambilan keizinan, pakar rujukan serta 
aliran kerja untuk penggunaan ubat di luar indikasi.  
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PHARMACOEPIDEMIOLOGIC AND COST EVALUATION OF OFF-
LABEL DRUG PRESCRIBING AMONG PAEDIATRIC PATIENTS AT 
HOSPITAL SUNGAI BULOH, SELANGOR, MALAYSIA 
 
ABSTRACT 
Off-label drug prescribing is common among paediatric patients. Prevalence 
and cost data on off-label drug prescribing among paediatric patients in Malaysia as 
well as the reasons behind the quantitative findings of previous studies remains 
unexplored. This research aimed to explore, evaluate and characterise the practice of 
off-label prescribing among paediatric patients in Hospital Sungai Buloh. Four studies 
were conducted using mixed-methodology approach to address the research 
objectives. The qualitative method provided a baseline and ground information on the 
awareness, knowledge, attitudes and views on off–label drug prescribing among 
paediatric patients. The quantitative method was used to determine the extent, nature 
and drug cost involved in off–label drug prescribing among paediatric patients and to 
assess learning needs among pharmacists and doctors towards off-label drug 
prescribing. The studies were conducted among the pharmacists and the doctors at the 
Pharmacy and the Paediatric Department of Hospital Sungai Buloh. Most of the study 
participants (93.4%) were familiar with the term off-label drug prescribing. About 
60% of the study participants were prescribing or dispensing off-label drugs 
unknowingly. There was a mismatch between the views of study participants and the 
findings of previous studies. The study participants were more concerned regarding 
the safety (63.7%) than the efficacy (40.7%) of off-label drugs Evidence-based 
practice was quoted as most important gate-keeping method. Disclosure to parents and 
obtaining consent was viewed as an important action to be taken when using off-label 
drugs. The act of ‘referring’ was quoted when discussing the decision making to 
xix 
 
prescribe or dispense off-label drugs and the features of preferred guidance options. 
Among the 4101 drug orders administered to 900 patients, 52.1% were off-label. Off-
label use accounted for RM61586.65 (54.1%) of the total drug cost. Most of the study 
participants (95.6%) indicated their interest to receive educational material or training 
regarding off-label prescribing. The policy or guideline was ranked as the most 
preferred (73.6%) training or guidance options. In conclusion, off-label drug 
prescribing is noticeably prevalent among paediatric patients at Hospital Sungai 
Buloh. The baseline and ground information on the perceived knowledge and views 
among pharmacists and doctors highlighted a disparity with actual findings from 
previous studies. Off-label drugs accounted for half of the total drug cost and this 
highlights the need for further cost-effectiveness studies. Efforts should be directed in 
addressing the exhibited learning needs in terms of identifying off-label drugs, 
integration of evidence, ensuring safety, consent taking, referral person and workflow 
to prescribe or dispense off-label drugs.   
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CHAPTER ONE 
 
GENERAL INTRODUCTION 
 
1.1 Introduction 
The Child Act 2001 in Malaysia, classifies a child is a person under the age of eighteen 
years (Percetakan Nasional Malaysia Berhad, 2005). The Malaysian classification of 
“children” or “paediatric” was adopted from the European Medicines Agency (EMEA) 
and the International Council for Harmonisation (ICH) classification which include 
neonates, infants, child and adolescents up to 18 years old.  
Table 1. 1 Age classification of paediatric population (Ceci et al., 2002) 
Age category Age range 
Preterm newborn <37 weeks gestation 
Term newborn 0 to 27 days 
Infants and toddlers 28 days to 23 months 
Child 2 to 11 years 
Adolescents 12 to 18 years 
 
Prescribing in children is associated with many challenges and one that has 
received considerable attention is off-label drug prescribing (World Health 
Organization, 2007, Keith, 2015). Off–label drug prescribing is generally defined as 
“drugs which are prescribed and used outside their licensed indications with respect to 
dosage, age, indication, or route” (Pandolfini and Bonati, 2005). Another term which 
is commonly used interchangeably with off–label drug prescribing is unlicensed drug 
use. Unlicensed drugs are those where the drug formulation is either modified, that are 
prepared as extemporaneous preparations, are imported or used before a license is 
granted, or chemicals used for therapeutic purposes (Pandolfini and Bonati, 2005).  
The issue with off-label drug prescribing is that the balance between efficacy 
and adverse effects has usually not been established. Previous studies reported that off-
label drug prescribing in paediatric patients was significantly associated with 
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incidence of adverse drug reactions (ADRs) (Horen et al., 2002, Neubert et al., 2004, 
Santos et al., 2008). Studies to evaluate efficacy of off-label drugs in paediatric patients 
reported findings that supports and opposes the effectiveness of some drugs in treating 
certain diseases (Falcon-Neyra et al., 2016, Maratea et al., 2016, Puttgen et al., 2016, 
Zeng et al., 2017). Despite the uncertainties in the outcome, drugs are continued to be 
used in an off-label manner among paediatric patients. 
This research focused on off–label drug prescribing among paediatric patients 
at Hospital Sungai Buloh.  Hospital Sungai Buloh is located approximately 25km from 
Kuala Lumpur in Mukim Batu, Gombak, in the central state of Selangor. The 620-
bedded hospital provides service to the population in the district of Gombak, Petaling 
and Kuala Selangor which makes up to 40% of the total population in the Selangor 
state. Details on the prevalence of off-label drug prescribing among paediatric patients 
and factors leading to such practice is discussed in-depth in the subsequent chapters. 
 
1.2 Off-label drug prescribing among paediatric patients in Malaysia: A brief 
overview 
Malaysia is a developing country with a population of approximately 30 million with 
7.2 million of them aged 15 years old and below (Health Informatic Centre, 2016). 
Just like children around the world, children in Malaysia are also prescribed with off-
label drugs. Doctors in many countries are allowed to prescribe drugs in an off-label 
manner, provided they adhere to certain pre-requisites (Ventola, 2009, Molyneux and 
Bogaert, 2010, Yamashiro et al., 2012). Likewise, in Malaysia, the existing acts and 
regulations does not prohibit doctors from prescribing drugs in an off–label manner. 
However, doctors in Malaysia are urged to obtain a written consent before prescribing 
an off-label drug (Director General of Health, 2016a). The reason for obtaining written 
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consent is to ensure that the risk of using off-label drugs is communicated with the 
patient (or parents and guardians) as well as to ensure proper documentation of such 
practice and serves as evidence should any undesirable outcome take place which can 
lead to malpractice lawsuits (Director General of Health, 2016a). 
Previously published data on the extent of off-label drug prescribing among 
paediatric patients in Malaysia are limited.  Three studies describing the extent of off-
label drug prescribing in Malaysian paediatric patients were published previously (Lee 
et al., 2013, Mohamad et al., 2015, Tan and Shah, 2016). One study highlighted that 
off–label drug prescribing occurs in 34.1% of the prescriptions for paediatric patients 
in the intensive care settings (Lee et al., 2013). The prevalence of off-label drug 
prescribing in the outpatient and ward settings were reported to be 35.6% and 60.8% 
respectively (Mohamad et al., 2015, Tan and Shah, 2016). Details on the findings of 
these studies as well as initiatives taken regarding off-label drug prescribing among 
paediatric patients are discussed further in detail in the next chapter. 
 
1.3 Study objectives 
The objective of this research was to explore, evaluate and characterise the incidence 
of off-label drug prescribing among paediatric patients in Hospital Sungai Buloh. 
The specific objectives were: 
i. to provide an overview of the awareness, knowledge and views of off–
label drug prescribing among paediatric patients. 
ii. to explore the knowledge, view and attitude of paediatric doctors and 
pharmacists towards off–label drug prescribing among paediatric patients. 
iii. to determine the extent, nature and drug cost involved in off–label drug 
prescribing among paediatric patients. 
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iv. to assess the learning needs among paediatric doctors and pharmacists 
towards off-label drug prescribing in paediatric patients. 
 
1.4 Justification of the study 
Studies on prevalence of off-label drug prescribing among paediatric patients were 
well-represented globally. However, the differences in the regulatory requirements, 
prescribing habits and drug utilization pattern as well as culture and patient 
characteristics in Malaysia, calls for further investigation and identification of the 
extent and nature of off-label drug prescribing among Malaysian paediatric patients. 
Moreover, there were limited studies conducted in Malaysia and the findings are 
insufficient to identify the magnitude of off-label drug prescribing among paediatric 
patients in Malaysia.   
The Ministry of Health (MoH) definition for off-label drug prescribing lacks 
clarity and inclusion of the many categories of off-label drug prescribing in Malaysia 
(Director General of Health, 2016a). A clearer definition for off-label drug prescribing 
in paediatric patients in Malaysia, which includes the many categories of such practice 
is required to be used for practice, research and future regulatory purposes. 
Given the lack of initiatives taken in Malaysia to improve drug use in paediatric 
population, the reasons why doctors and pharmacists choose to prescribe and dispense 
off-label drugs to paediatric patients, and how much knowledge they have regarding 
this practice as well as what would be a good guidance to them is also poorly 
understood. Since decades ago till now, knowledge and healthcare professionals’ 
personal characteristics have been reported as a factor influencing prescribing and 
dispensing habits (Hemminki, 1975, Bradley, 1992, Caamaño‐Isorna et al., 2005, 
Ljungberg et al., 2007). Ultimately, it is known that interventions to change prescribing 
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or dispensing behavior are more likely to be effective if they are perceived as relevant 
by the recipients (Cutts and Tett, 2003). Therefore, further understanding and 
investigation into knowledge and personal characteristics of paediatric doctors and 
pharmacists is warranted to in order to recognise the reasons behind off-label use of 
drugs in paediatric patients as well as to identify possible knowledge gap.  
Findings on the cost incurred by off-label drug use is scarce and were reported 
from countries which have different healthcare financing systems compared to 
Malaysia. Additionally, in the era of financial constraint especially in healthcare 
financing, the practice of optimal allocation of limited resources sometimes fail to 
provide importance to drugs without substantial evidence on effectiveness and safety 
(Drummond et al., 2008, Largent and Pearson, 2012). Therefore, there is need to 
identify the cost of off-label drugs used in paediatric patients in order to guide 
allocation, coverage and reimbursement decisions of off-label drugs in paediatric 
patients. 
 
1.5 Overview of the thesis 
Chapter 2 consists of the literature review which was initiated with the brief 
discussion on the factors leading to off-label drug prescribing among paediatric 
patients and the initiatives taken around the world to improve drug use in children. 
Additionally, the worldwide scenario of the prevalence of off-label drug prescribing 
in paediatric patients as well as the extent and nature of off-label drug prescribing in 
paediatric patients was collated and discussed in this chapter. A brief discussion on the 
off-label drug expenditure as well as the reimbursement and coverage for off-label 
drugs were also included in this chapter. Lastly, the concerns on off-label drug 
prescribing among paediatric patients was outlined and briefly discussed. 
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In chapter 3, the general methodology of the study is presented. The 
methodology employed in the four parts of the study was explained, beginning with 
the explanation and justification of the methodology used to conduct the systematic 
review of awareness, knowledge and views of off-label drug prescribing among 
paediatric patients; followed by the methodology for the qualitative interview among 
hospital-based paediatric doctors and pharmacists. Then the methodology used to 
quantitatively analyse the prevalence, nature and extent of off-label drug prescribing 
among paediatric patients as well as the drug cost analysis was also discussed. Lastly, 
the methodology used for the learning needs assessment survey conducted among the 
hospital-based paediatric doctors and pharmacists was deliberated. 
Chapter 4 presented the findings from the systematic review of awareness, 
knowledge and views of off-label drug prescribing among paediatric patients. Then in 
chapter 5, the findings of the qualitative interview among hospital-based paediatric 
doctors and pharmacists was presented. Chapter 6 contains the description of the 
findings from the study on prevalence, nature and extent of off-label drug prescribing 
in paediatric patients as well as the drug cost analysis. In chapter 7, the findings of 
the learning needs assessment survey are presented. Finally, chapter 8 draws the thesis 
to an overall conclusion, followed by recommendations for future research. 
 
1.6 Significance of the study 
This study serves as an addition to the vast body of existing knowledge portrayed in 
the literature regarding the worldwide scenario of off-label drug prescribing among 
paediatric patients. The findings of this research provide information on off-label drug 
prescribing among paediatric patients from a niche population in Malaysia, creating 
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basis for further investigation of off-label drug prescribing among paediatric patients 
around the country to obtain a nationwide analysis of the situation.  
The systematic review serves as the baseline data of what is already known 
regarding awareness, knowledge and views of off-label drug prescribing in paediatric 
patients among healthcare professionals, parents and children. Moving forward, the 
qualitative study, will provide ground information to help in providing deeper 
understanding on the knowledge, view and attitude of paediatric doctors and 
pharmacists on off–label drug prescribing among paediatric patients in Hospital Sungai 
Buloh. The paediatric doctors ultimately decide what drug to offer to their patients and 
the pharmacists dispenses the drug according to the doctors’ prescription. Sometimes, 
the decision on the doctors’ choice of drug for their patients is altered based on 
recommendations from the pharmacists. Therefore, it is important that the perspectives 
of the paediatric doctors and pharmacists on off-label drug prescribing are understood. 
This is especially important in the treatment of paediatric patients, whose maturing 
bodies may be more sensitive to the drug’s effects. The results from this study will 
provide an understanding of factors that influence a paediatric doctor’s decision to 
prescribe and a pharmacist’s decision to dispense an off-label drug to paediatric 
patients, thus may lead to strategies for promoting more informed off-label drug 
prescribing among paediatric patients. 
From a practice standpoint, the off-label drug cost analysis performed in this 
study is relevant and timely for the healthcare sector, which is currently in the midst of 
significant changes in the way of financing the provision of healthcare in the country. 
Currently the healthcare financing in Malaysia uses the two-tiered system whereby the 
funding sources for the public medical services are mainly derived from tax revenue 
whereas the private sector medical services are at large financed through out-of-pocket 
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expenses. Through healthcare reform strategies, the future proposed healthcare 
financing system will mainly involve insurance scheme and data on cost of off-label 
drugs will be an important element in planning the reimbursement decision framework. 
The learning needs assessment will identify the level of knowledge and the need 
for training or guidance to be provided on off-label drug prescribing in paediatric 
patients among paediatric doctors and pharmacists. Rather than assuming that all 
doctors and pharmacists needs guidance on off-label drug prescribing among paediatric 
patients, the management can make informed decisions on what are the knowledge 
gaps (if any) and decide the best ways to address the knowledge gap on off-label drug 
prescribing in paediatric patients that exists among paediatric doctors and pharmacists. 
 
1.7 Operational definition 
Several fundamental concepts and terms that were used in this thesis are classified as 
the operational definitions (Table 1.2). 
Table 1. 2 Operational definitions used in the thesis 
Terms Operational definitions 
Pharmacoepidemiology The pharmacoepidemiology component was the 
study of the extent and nature of off-label drug 
prescribing among paediatric patients in Hospital 
Sungai Buloh. 
Paediatric Paediatric refers to any individual below or at the 
age of 18 years old. The term ‘children’ is also 
used interchangeably with ‘paediatric’. 
Off-label drug prescribing The use of a drug outside Drug Control Authority 
(DCA) indication (Director General of Health, 
2016a) with regards to age, indication, dose and 
route of administration, the use of a drug without 
dosing information in children, use without 
safety/efficacy/tolerability data in children and 
contraindicated and unapproved in children. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
2.1 Introduction 
This literature review chapter is aimed to identify similar work done on the practice of 
off-label drug prescribing among paediatric patients and objectively report the updated 
knowledge as well as the gaps identified in the literature that requires further 
investigations within the area. This chapter has five related subtopics. First, the factors 
leading to off-label drug prescribing in paediatric patients we gathered and discussed. 
Secondly, the initiatives taken by regulatory, legislative, governmental and 
professional bodies to improve drug use in children, particularly in Malaysia, were 
discussed. This was followed by the discussion on the worldwide overview of the 
prevalence of off-label drug prescribing in paediatric patients. This overview was 
compiled and discussed according to the various paediatric treatment settings. Next, 
the cost of off-label drugs was briefly discussed in relation to the off-label drugs 
expenditure and reimbursement as well as coverage for off-label drugs. Lastly, the 
concerns related to off-label drug prescribing in paediatric patients were listed and 
discussed. The chapter was finalised with a chapter summary. 
 
2.2  Factors leading to off-label drug prescribing in paediatric patients 
The factors associated with off-label drug prescribing in paediatric patients are 
multifaceted and the discussion on this prescribing trend begins with the presumption 
that it can be viewed as standalone segments but the problem is, it is difficult to do so. 
For example, a parent’s decision to accept or refuse a treatment for their children is 
based on many factors which is greatly influenced by input from healthcare 
professionals (Lantos, 1987, Partridge et al., 2005). Likewise, in clinical trials, as with 
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medical treatment, obtaining consent is an important aspect in determining 
participation of children. These factors tend to be realistically interconnected hence 
addressing these factors requires a holistic approach.  
 
2.2.1  Clinical trial factor 
The hurdles associated with conducting clinical trials in children is intertwined in 
every stage of a clinical trial but mainly in choosing the right methodology (Conroy et 
al., 2000b) and outcome to measure (Smyth and Weindling, 1999), logistical planning 
and financial aspects of the trial (Choonara, 2000, Gennery, 2000), recruitment and 
retention of participants, and identifying and managing trial sites and staffs (Cohen, 
1999). Due to these challenges, many drugs lack scientific evidence derived from 
clinical trials, to support its use, efficacy and safety in children. This causes drugs to 
be used in an off-bale manner. Alternative study designs can be considered to 
overcome the challenges of paediatric clinical trials (Sable et al., 2017). 
 
2.2.2 Drug factor 
Another factor that arises significantly as a result of the difficulties in conducting 
clinical trials and research in children is the drug factor. Many established and 
commonly used drug references fail to provide adequate dosing information for drug 
use in children due to insufficient data from clinical trials conducted in children 
(Wilson, 1999, Tan et al., 2003, Benjamin et al., 2006, Permala et al., 2010). Clinical 
trials or research conducted specifically for paediatric drug formulation development 
endure the same sets of challenges including methodological and ethical requirements 
for paediatric trials, high developmental costs, and a small and fragmented market 
(Ivanovska et al., 2014). The lack of paediatric dosing information and paediatric 
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formulations often leaves healthcare professionals no alternative but to use adult 
medicines in an off-label or unlicensed manner for their paediatric patients.  
 
2.2.3 Healthcare professional factor 
Studies conducted in the past have established that complacency or the need to fulfil 
what healthcare professionals perceived as being patients’ or parents’ expectations, 
lead to overprescribing and misprescription (Lopez-Vazquez et al., 2012, Sirota et al., 
2017). Some of these perceptions held by doctors on patients’ and parents’ expectation 
is sometimes wrongly assessed and interpreted (Stivers et al., 2003). A mere act of 
questioning a doctor’s treatment can send out a signal that parents are expecting 
prescriptions from their doctors (Mangione-Smith et al., 2006) and most of the time, 
these expectations are obliged. Moreover, healthcare professionals were reported to 
have varying degree of knowledge and low level of awareness on off-label drug 
prescribing in paediatric patients (Mukattash et al., 2011a, Mukattash et al., 2011b), 
resulting in high possibilities of fulfilling the patients’ or parents’ expectations on 
treatment, with off-label drugs. Healthcare professionals were also reported to not seek 
informed consent from parents when prescribing off-label drugs (McLay et al., 2006) 
causing deficiency in knowledge among parents or caregivers regarding off-label drug 
prescribing in paediatric patients. Lastly, it is discreditable to come upon the fact that 
off-label drug prescribing in paediatric patients also occurs as a result of unethical 
promotion and encouragement by pharmaceutical companies (Kesselheim et al., 
2011). 
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2.2.4 Parents or caregivers factor 
Factors associated with parents or caregivers are more behavioural in nature and has 
an indirect impact on the off-label drug prescribing in paediatric patients. However, 
parents or caregivers factor has a great direct impact on healthcare professional and 
clinical trial factor, making it a significant point of discussion. Firstly, due to lack of 
knowledge on off-label drug prescribing in paediatric patients, many parents 
‘accepted’ the use of off-label drug for their children (Lenk et al., 2009, Bang et al., 
2014, Shah, 2017). Upon gaining knowledge on off-label drug prescribing, many 
parents tend to ask for a change of treatment (Bang et al., 2014) or refuse the use off-
label drugs (Lenk et al., 2009). Secondly, desperation for treatment was demonstrated 
in parents of children with illness. Demanding for, and accepting futile treatments 
(Forbat et al., 2015) as well as making emotional decisions in the disease management 
of their children have rendered parents to be in a desperate position and ultimately 
adds pressure on healthcare professionals to provide treatment for their patients. 
Additionally, parents or caregivers usually perform multiple tasks in the process of 
care of their children with illness and this can go on for a long period of time if the 
child suffers from chronic illnesses. Over time, parents or caregivers are at risk of 
burnout associated with the complexity and diversity of responsibilities of care 
(Sullivan-Bolyai et al., 2003). This, coupled with the desperation for treatment and the 
genuine hope to positively and promptly manage the illness faced by their children, 
creates the basis for the expectations that parents or caregivers place on their healthcare 
providers.  
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2.3 Initiatives concerning off-label drug prescribing in children 
Several initiatives were introduced and implemented globally to gain better knowledge 
about effects of drugs in children and to guide health care professionals to use quality 
drugs that are efficacious and causes no harm to children. This includes the drug 
licensing which was aimed to ensure drug quality, safety and efficacy. Unfortunately, 
a large proportion of drugs for children lack licensing or marketing authorisations 
(Riedel et al., 2016).  This suggest that a lot of drugs used for children still lacks 
evidence derived from pharmacokinetic, dose finding, or formulation studies properly 
conducted in the paediatric population (Coté et al., 1996, Rocchi and Tomasi, 2011) 
hence causing it to be used in an off-label manner. 
 
2.3.1 Global initiatives 
The United States of America (US) and the European Union (EU) (Choonara, 2007) 
legislative and regulatory frameworks were at the forefront to increase the number of 
paediatric studies required to improve paediatric labelling. To follow suit, other 
countries, for example Canada (Turner et al., 2014), Australia (Hoppu et al., 2012), 
Japan (Uchiyama, 2002), China (Zheng et al., 2017) and Korea (Yang et al., 2008) 
have somewhat attempted to take other forms of initiatives in order to provide safe and 
efficacious drugs to children. However, no significant difference in the resulting 
situation was found.  
 
2.3.2 Malaysian initiatives 
In Malaysia, the DCA is tasked with ensuring the quality, safety and efficacy of drugs 
through the registration, including quality control, inspection and licensing and post-
registration activities. Part of the registration requirement is to provide specific 
14 
 
indication(s) for a drug to be approved by DCA. This indication is referred to as the 
DCA indication. In the year 2012, a directive from the Director-General of Health 
marked the initial endorsement on the definition of off-label drug prescribing by MoH 
(Appendix 1). The directive also urged for written consent to be taken for off-label use 
of drug. However, awareness regarding the existence of the consent form was 
questionable and the use of the form was uncommon (Director General of Health, 
2016a).  
In the year 2015, a list of drugs commonly used off-label among Malaysian 
patients was prepared by the Pharmaceutical Services Division. The drugs included in 
the list were approved by the Director-General of Health to be used in an off-label 
manner and were exempted from the written consent process. Unfortunately, 95% of 
the drugs listed were commonly used off-label among adult patients. Paediatricians 
were still required to obtain written consent for all drugs prescribed in an off-label 
manner. Institution level initiatives were taken to guide the paediatricians to identify 
common off-label uses of drugs in paediatric patients and to prompt them to obtain 
written consent when such drugs were prescribed (personal communication). Effort 
needs to first be devoted to build a standardised nationwide framework to further 
address the needs for better medicine for children in Malaysia.  
Overall, despite numerous global legislative and regulatory initiatives, children 
are still found to be underprivileged with regards to participation in clinical trials, 
labelling of drugs prescribed to children, availability of appropriate drug formulations 
for children as well as the evidence-based use of drugs which led to off-label drug 
prescribing in children (Corny et al., 2015).This suggest that legislative, regulatory, 
governmental and professional initiatives alone may not be sufficient to improve drug 
use in children. Behavioural and knowledge aspects related to prescribing in children, 
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particularly off-label drug prescribing, also need to be evaluated and consolidated as 
part of the concerted efforts to narrow the gaps in prescribing for children. 
 
2.4 Overview of the prevalence studies on off-label drug prescribing in 
paediatric patients 
In total, 108 studies performed between 1996 and 2016 on off-label drug prescribing 
in paediatric patients were reviewed. Most of the studies (74/108) were conducted 
from the year 2006 to 2016. The number of patients ranged from 34 to 312 million and 
the number of prescriptions ranged from 88 to 484 million. Most of the studies 
(68/108) were prospective studies. These studies reported that the proportion of 
paediatric patients who received at least one off-label drug was between 4 to 100%. 
The overall rates of off-label drug prescribing in paediatric patients reported was 1.2 
to 99.7%.  
 
2.4.1 Off-label drug prescribing in neonatal intensive care units 
There were 24 studies performed between 1999 and 2016 which involved neonatal 
wards particularly the neonatal intensive care unit (NICU) (Conroy et al., 1999, Avenel 
et al., 2000, Barr et al., 2002, O’Donnell et al., 2002, Cortizas et al., 2003, Dell’Aera 
et al., 2007, Kumar et al., 2008, Prandstetter et al., 2009, Dessì et al., 2010, Neubert et 
al., 2010, Lass et al., 2011b, Nguyen et al., 2011, Carvalho et al., 2012, Oguz et al., 
2012, Jain et al., 2014, Kieran et al., 2014, Laforgia et al., 2014, Mesquita et al., 2014, 
Thomas, 2014, Riou et al., 2015, Silva et al., 2015, de Souza et al., 2016, Cuzzolin and 
Agostino, 2016, Schweigertova et al., 2016) (Table 2.1). The number of patients 
ranged from 34 to 2304 with the number of prescriptions ranging from 88 to 8891. 
Rates of off-label drug prescribing among paediatric patients in the NICU ranged from 
27.7% to 95.6%. 
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Table 2. 1 Summary of studies reporting off-label drug prescribing in NICUs 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n  
(no. of 
prescriptions) 
% OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category of 
OL 
Common OL 
drug or drug 
group 
Conroy S et al, 1999 United 
Kingdom 
13-week period 
(P) 
n/r Data Sheet 
Compendium 
1998–99 
70  
(455) 
54.7 90.0 
(UL/OL) 
Dose Benzyl-
penicillin 
*Avenel S et al, 2002 France 1-month period 
(n/r) 
0-128 days n/r 47  
(257) 
62.0 
(pre-
mature 
infants) 
 
64.0 
(new-
borns) 
n/r Age n/r 
Barr J et al, 2002 Israel 4-month period 
(P) 
n/r PDR 2000 105  
(525) 
63.0 n/r Dose Theophylline 
O'Donnell CPF et al, 2002 Australia 10-week period 
(P) 
n/r Australian 
Prescription 
Products 
Guide 2002 
 
97  
(1442) 
47.0 80.0 
(UL/OL) 
Indication Morphine 
*Cortizas BF et al, 2003 Spain n/r n/r Dirección 
General de 
Farmacia y 
Productos 
Sanitarios. 
346  
(n/r) 
n/r 17.6 Age n/r 
Dell'Aera M et al, 2007 Italy 2-month period 
(P) 
n/r SmPC 34  
(176) 
44.3 n/r Dose Systemic 
antibiotics 
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Table 2.1 - Continued 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n 
(no. of 
prescriptions) 
% OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category of 
OL 
Common OL 
drug or drug 
group 
Kumar P et al, 2008 United 
States 
3-year period 
(R) 
n/r USFDA 
approval for 
use in 
neonates 
2304  
(n/r) 
n/r 20.0 n/r Fentanyl 
*Prandstetter C et al, 2009 Austria  3-month period 
(R) 
n/r n/r 84  
(748) 
34.0 77.0 n/r n/r 
Dessı A et al, 2010 Italy 1-month period 
(P) 
n/r Product data 
sheets 
38  
(88) 
47.7 n/r Age Gentamicin  
Neubert A et al, 2010 Germany 11-month period 
(P) 
n/r SmPC 183  
(1978) 
34.0 70.0 
(OL/UL) 
Age1 Analgesics 
and 
cardiovascular 
drugs 
Lass J et al, 2011 Estonia 12-month 
periodd 
(P) 
postnatal 
age <29 
days 
SmPC 490  
(1981) 
65.0 98.0 
(UL/OL) 
n/r Antibacterials,  
Nguyen KA et al, 2011 France 4-month period 
(P) 
>32 weeks 
GA 
SmPC in 
Vidal 2009 
 
55  
(265) 
29.4 71.0 Age Ferrous 
fumarate 
Carvalho CG et al, 2012 Brazil 6-week period 
(P) 
n/r USFDA list of 
approved 
drugs 
 
129  
(318) 
27.7 78.7 
(UL/OL) 
Age Dose: 
ampicillin, 
Age: glycerin,  
Indication: 
meto-
clopramide 
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Table 2.1 - Continued 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n 
(no. of 
prescriptions) 
% OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category of 
OL 
Common OL 
drug or drug 
group 
Oguz SS et al, 2012 Turkey 1-month period 
(P) 
n/r Package insert 
in Rx 
MediaPharma 
2010 version 
10.0.0 
interactive 
program 
464  
(1315) 
62.32 
(OL/ 
UL) 
n/r Lack of 
information 
n/r 
Kieran E et al, 2013 Ireland 2-month period 
(P) 
born 
before 35 
completed 
weeks of 
gestation 
SmPC 
contained in 
the packaging 
insert 
provided with 
the 
medication. 
110  
(900) 
32.0 n/r n/r Benzyl-
penicillin and 
gentamicin 
Jain S et al, 2014 India 3-month period  
(P) 
n/r USFDA list of 
approved 
drugs 
156 
(568) 
50.3 n/r Age Anti-infective 
and 
antiepileptic 
drugs 
Laforgia N et al, 2014 Italy 1-month period 
(P) 
n/r Specific 
marketing 
authorization 
126  
(483) 
46.5 n/r n/r Frusemide 
Mesquita M et al, 2014 Paraguay 3-month period 
(P) 
0 - 28 days USFDA list of 
approved 
drugs 
105  
(92) 
n/r 39.0 
(OL/UL) 
n/r Antibiotics 
Thomas A et al, 2014 South Africa 3-month period  
(P) 
≤ 28 days Package insert 112  
(759) 
51.0 91.0 
(OL/UL) 
Dose Amino-
phylline 
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Table 2.1 - Continued 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n 
(no. of 
prescriptions) 
% OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category of 
OL 
Common OL 
drug or drug 
group 
Riou S et al, 2015 France 1-year period 
(P) 
n/r SmPC in a 
French 
independent 
formulary 
named 
Theriaque 
2013 
910  
(8891) 
59.5 94.8 
(OL/UL) 
Age Calcium 
folinate 
Silva J et al, 2015 Portugal 6-month period 
(R) 
0-27 days 
of 
postnatal 
age 
SmPC 218  
(1011) 
52.7 69.7 
(OL/UL) 
Dose and/or 
frequency 
Age: 
Paracetamol, 
Amikacin, 
Fluconazole   
                                                  
Indication: 
Midazolam   
                                                                                 
Route: 
Calcium 
Polystyrene 
Sulphonate   
                                                                                       
Dose and/or 
frequency: 
Gentamicin, 
Ampicillin, 
Paracetamol 
 
Cuzzolin L et al, 2016 Italy 1-day period 
(P) 
n/r Package 
insert, SmPC 
220  
(720) 
59.0 n/r Age Fluconazole, 
fentanyl, 
ranitidine 
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Table 2.1 - Continued 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n 
(no. of 
prescriptions) 
% OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category of 
OL 
Common OL 
drug or drug 
group 
de Souza et al, 2016 Brazil 6-month period 
(R) 
≤ 28 days Information 
leaflets 
 
192  
(3290) 
95.6 99.5 Age Heparin, 
fentanyl, 
multivitamin 
Schweigertova J et al, 2016 Slovakia 6-month period 
(n/r) 
<1month Slovak SmPC 
in SIDC 
homepage 
 
202  
(962) 
43.0 87.1 Age1 Ketoconazole 
GA = gestational age, n/r = not reported, OL = off-label, P = Prospective, PDR = Physicians’ Desk Reference, R = Retrospective, SIDC = State Institute for Drug Control, 
SmPC = Summary of Product Characteristics, UL = Unlicensed, USFDA = United States Food and Drug Administration, *Data tabulated from study abstract as full-text was 
available in other language besides English, 1This study only analysed age category for off-label drug use, 2Study reported OL/UL rate based on two references sources, data 
reported is based on national database
21 
 
A total of twelve studies reported a comparison of off-label drug prescribing 
rates in preterm and full-term babies. Six studies reported that off-label drug 
prescribing rates were higher in full-term babies compared to preterm babies (Avenel 
et al., 2000, Dell’Aera et al., 2007, Dessì et al., 2010, Carvalho et al., 2012, Laforgia 
et al., 2014, Schweigertova et al., 2016). The remainder of the studies reported 
otherwise (Neubert et al., 2010, Lass et al., 2011b, Kieran et al., 2014, Riou et al., 
2015, Silva et al., 2015, de Souza et al., 2016). A study by O’Donnell et al. reported 
that off-label drug prescribing rate was higher in infants who weighed ≤1000g 
(O’Donnell et al., 2002). The two most common categories of off-label drug 
prescribing among paediatric patients in the NICU were age and dose. 
The drug group and drug reported to be most commonly used in an off-label 
manner among paediatric patients in the NICU were systemic antibiotics and fentanyl. 
Even though the drugs used among paediatric patients in the NICU were mostly off-
label, some studies demonstrated that such use were justified with evidence on the 
safety and efficacy of drugs in the neonates. The study by Jain et al. reported that one 
third of drugs which lacks United States Food and Drug Administration (USFDA) 
approval had level I-II evidence of safety and efficacy for use in neonates (Jain et al., 
2014) whereas Kumar et al. identified that more than 90% of all prescriptions for off-
label use of parenteral medications were for drugs with level I evidence of efficacy 
and safety (Kumar et al., 2008). 
 
2.4.2 Off-label drug prescribing in paediatric intensive care units 
Nine studies performed between 1996 and 2016 were conducted among paediatric 
patients in the paediatric intensive care unit (PICU) (Turner et al., 1996, Carvalho et 
al., 2003, Gavrilov et al., 2003, Bavdekar et al., 2009, Yang et al., 2011, Ferreira et al., 
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2012, Czaja et al., 2015, Jobanputra et al., 2015, García-López et al., 2016) (Table 
2.2).  The majority of the studies (8/9) were conducted prospectively with one study 
(Gavrilov et al., 2003) which was conducted at two different hospitals with data from 
one hospital collected retrospectively and the other prospectively. The number of 
patients ranged from 42 to 66896. The off-label drug prescribing rates resulting from 
these studies ranged from 23% to 70.6% with the proportion of paediatric patients in 
the PICU receiving at least one off-label drug ranged from 62.7% to 100%. The most 
common categories of off-label drug prescribing among paediatric patients in the 
PICU were dose, age, and indication. The drugs commonly used in an off-label manner 
among paediatric patients in the PICU were morphine, midazolam, chloral hydrate, 
frusemide, triclofas, salbutamol, ipratropium bromide, dopamine, fentanyl, adrenaline, 
noradrenaline, and oseltamivir.  
Subgroup analysis was performed in the study by García-López et al. and 
Ferreira et al. showed that off-label drug prescribing rates decreased with higher age 
groups (Ferreira et al., 2012, García-López et al., 2016). This trend was not depicted 
in the study by Jopanputra et al. and Bavdekar et al, whereby the off-label drug 
prescribing rates were higher in children aged 1-12 months and 5-12 years old 
compared to age 1-5 years old (Bavdekar et al., 2009, Jobanputra et al., 2015).   
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Table 2. 2 Summary of studies reporting off-label drug prescribing in PICUs 
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n (no. of 
prescriptions) 
% 
OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category 
of OL 
Common OL drug 
or drug group 
Turner S et al, 1996 United 
Kingdom 
4-month period 
(P) 
1 day - 15 
years 
ABPI data 
sheet 
compendium 
1995-96 
166 (862) 23.0 70.0 n/r Morphine, 
midazolam, chloral 
hydrate1 
Carvalho PRA et al, 2003 Brazil 6-week period 
(P) 
1 month – 18 
years old 
 USP DI 2001 51 (747) 49.5 100.0 n/r Frusemide 
Gavrilov V et al, 2003 Israel 7-month period 
(R&P)1 
0-18 years PDR 2000 and 
the Israel Drug 
Compendium 
1995 
158 (874) 
 
41.9 
(OL/
UL) 
 
n/r Age Epinephrine, 
midazolam, triclofas,                                                  
salbutamol, 
ipratropium bromide                                                
Bavdekar SB et al, 2009 India 6-month period 
(P) 
28 day-12 
years old 
BNF version 
2005 
300 (2237) 70.6 96.0 Dose Dopamine  
Yang CP et al, 2011 United States 2-month period 
(P) 
n/r USFDA 
approval 
status as stated 
in Thomson 
Micromedex 
online 
database 
n/r (49707) 66.9 n/r Age2 Salbutamol 
Ferreira LDA et al, 2012 Brazil 9-month period 
(P) 
n/r ANVISA 
package insert 
list 
73 (1054) 23.4 86.0 Dose Fentanyl  
Czaja AS et al, 2015 United States 1-year period  
(n/r) 
0-18 years USFDA list of 
approved 
drugs 
66896 (n/r) n/r 85.0 Indication Cardiovascular drugs 
Jobanputra N et al, 2015 India 12-month period 
(P) 
1 month-12 
years 
Product insert 
provided by 
the 
manufacturer 
482 (1789) 41.3 62.7 Indication Adrenaline, 
Noradrenaline, 
Oseltamivir 
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Table 2.2 - Continued  
Author, Year Country 
Study duration 
(Study design) 
Age group 
Primary 
reference 
source 
n (no. of 
prescriptions) 
% 
OL 
% of 
patients 
receiving 
at least 1 
OL drug 
Common 
category 
of OL 
Common OL drug 
or drug group 
García-López I et al, 2016 Spain 6-week period 
(P) 
0-18 years  SmPC 
 
42 (696) 52.9 100.0 Indication Fentanyl 
ABPI = The Association of the British Pharmaceutical Industry, ANVISA = National Health Surveillance Agency, BNF = British National Formulary, n/r = not reported, OL = 
off-label, P = Prospective, PDR = Physicians’ Desk Reference, R = Retrospective, SmPC = Summary of Product Characteristics, UL = Unlicensed, USFDA = United States 
Food and Drug Administration, USP DI = United States Pharmacopeia Drug Information for the Health Care Professional, 1 This study was conducted at two different hospitals 
with data from one hospital collected retrospectively and the other prospectively, 2 This study only analysed age category for off-label drug use 
 
